We propose to further investigate the pathophysiological role and the potential diagnostic therapeutic relevance of the insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) in benign prostatic hyperplasia (BPH). Over the past several years, we have elucidated an intricate network of molecular interactions of IGFs and related molecules in the prostate. We have shown that IGFs, IGF receptors, IGFBPs and IGFBP proteases are all present in prostatic cells, tissues, and fluids, and provide an important growth regulatory system. We have identified several IGF-related abnormalities in prostatic stromal cells (PC-S) from BPH tissues. One of these is the under-expression of WT-1, a tumor suppressor gene which regulates IGF-II and IGF receptor gene transcription in prostate stromal cells. Abnormal expression of WT-1 in BPH leads to dys-regulated expression of critical components of the IGF growth cascade. We also noted that transforming growth factor-D (TGFD), which has a growth-inhibitory effect on PC-S, dramatically stimulates the production of the growth-inhibitory IGFBP-3 in PC-S derived from normal but not BPH tissues. We thus hypothesize that the prostatic stroma is the site of the primary molecular defect in BPH and that this defect involves dys-regulated IGF and IGFBP gene transcription at both the basal state and in response to modulating factors. In our proposed studies, we plan to address the following experimental goals: 1) To further characterize the nature of the WT-1 defect and its role in dys-regulation of the IGF axis in BPH by the use of CDNA sequencing and by employing antisense oligomers and CDNA transfection to look for reversion of the molecular and biological phenotype; 2) To identify other molecular abnormalities in BPH stromal cells by differential display and northern analysis of MRNA from normal and BPH sources; 3) To examine the biological effects of molecular abnormalities in IGF axis components and other elements on the phenotype of prostatic stromal cells by evaluating proliferation, apoptosis and differentiation in response to modulating factors (such as TGFD and other regulators); and 4) To use our findings in vitro to identify IGF-related or other (non IGF-related) in situ markers in the tissues of men with BPH. If successful , our findings may provide new targets for drug development and other novel therapeutic interventions or diagnostic strategies for use in men with BPH.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK047591-06
Application #
2770443
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1993-09-30
Project End
1999-03-31
Budget Start
1998-09-15
Budget End
1999-03-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Shim, Melanie L; Levitt Katz, Lorraine E; Davis, Jason et al. (2004) Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. Growth Horm IGF Res 14:216-25
Wetterau, Lawrence A; Francis, Malik J; Ma, Liqun et al. (2003) Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J Clin Endocrinol Metab 88:3354-9
Moore, Michael G; Wetterau, Lawrence A; Francis, Malik J et al. (2003) Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105:14-9
Liu, Bingrong; Weinzimer, Stuart A; Gibson, Tara Beers et al. (2003) Type Ialpha collagen is an IGFBP-3 binding protein. Growth Horm IGF Res 13:89-97
Franklin, Sherry Lynn; Ferry Jr, Robert J; Cohen, Pinchas (2003) Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 88:900-7
Ngo, Tung H; Barnard, R James; Cohen, Pinchas et al. (2003) Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res 9:2734-43
Ngo, Tung H; Barnard, R James; Leung, Pak-Shan et al. (2003) Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144:2319-24
Monzavi, Roshanak; Cohen, Pinchas (2002) IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab 16:433-47
Rajah, Roopmathy; Lee, Kuk-Wha; Cohen, Pinchas (2002) Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13:163-71
Grimberg, Adda; Liu, Bingrong; Bannerman, Peter et al. (2002) IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 21:327-35

Showing the most recent 10 out of 35 publications